JSPR

9.18014.60%
JS

Jeetinder Singh Mahal

President, CEO, Interim CFO & Director

Mr. Jeetinder Singh Mahal, also Known as Jeet, M.B.A., M.E., M.B., serves as President, CEO, Interim Chief Financial Officer and Director at Jasper Therapeutics, Inc. and served as its Chief Financial Officer since December 2019 until September 23, 2023 and served as its Chief Operating Officer since March 21, 2022. He served as Business Officer of Jasper Therapeutics, Inc. since December 2019 and served as its Corporate Secretary since September 2021 until September 23, 2023. He worked at Xarelto. Mr. Mahal joined Jasper Therapeutics, Inc. in 2019 as Chief Finance and Business Officer and has led Finance, Business Development, Marketing and Facilities/ IT since the company’s inception. Prior to joining Jasper, Mr. Mahal worked at Portola Pharmaceuticals, Inc. from August 2008 to December 2019, where Mr. Mahal held a number of positions of increasing leadership, as Vice President, Strategic Marketing from January 2019 to December 2019 and Vice President, Business Development from February 2013 to December 2018. While at Portola Pharmaceuticals, Inc., Mr. Mahal led the execution of multiple business development Partnerships for Andexxa®, Bevyxxa® and cerdulatinib. Earlier in his career, from January 2006 to September 2008, Mr. Mahal served as Director of Business and New Product Development at Scios Inc. (Johnson & Johnson). Prior to Scios, Mr. Mahal served as a Managing Consultant for Navigant Consultingâ s Life Sciences practice. He started his career as a development scientist at COR Therapeutics working on a number of the companyâ s pipeline products. Mr. Mahal holds a BA in Molecular and Cell Biology from the University of California at Berkeley, an MBA from the Fuqua School of Business at Duke University, a Masters s degree in Molecular and Cell Biology from Illinois Institute of Technology and a Master’s degree in engineering from North Carolina State University.

Positions